Glutathione S-transferase P1-1 (GSTP1-1) Inhibits c-Jun N-terminal Kinase (JNK1) Signaling through Interaction with the C Terminus*

Tieli WangDagger , Pinar ArifogluDagger , Ze'ev Ronai§, and Kenneth D. TewDagger

From the Dagger  Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 and the § Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, New York 10029

Received for publication, February 13, 2001, and in revised form, March 8, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

c-Jun N-terminal kinase (JNK)-mediated cell signaling pathways are regulated endogenously in part by protein-protein interactions with glutathione S-transferase P1-1 (GSTP1-1) (1). Using purified recombinant proteins, combined with fluorescence resonance energy transfer technology, we have found that the C terminus of JNK is critical to the interaction with GSTP1-1. The apparent Kd for full-length JNK was 188 nM and for a C-terminal fragment (residues 200-424) 217 nM. An N-terminal fragment (residues 1-206) did not bind to GSTP1-1. Increased expression of the C-terminal JNK fragment in a tetracycline-inducible transfected NIH3T3 cell line produced a concentration-dependent increase in the kinase activity of JNK under normal, unstressed growth conditions indicating a dominant-negative effect. This suggests that the fragment can compete with endogenous full-length functional JNK resulting in dissociation of the GSTP1-1-JNK interaction and concomitant JNK enzyme activation. By using an antibody to hemagglutinin-tagged C-JNK, a concentration-dependent co-immunoprecipitation of GSTP1-1 was achieved. These data provide evidence for direct interactions between the C-terminal of JNK and GSTP1-1 and a rationale for considering GSTP1-1 as a critical ligand-binding protein with a role in regulating kinase pathways.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

c-Jun N-Terminal kinase (JNK),1 or stress activated kinase, is a member of the mitogen activated stress kinase family (MAPK), which also includes extracellular signal regulated kinase and p38-MAPK. JNK activation was initially identified as a cellular response to environmental stresses, proinflammatory cytokines, and interleukins (2). In addition, the JNK pathway participates in activating transcription factor 2 (3), ELK-1 (4), and the Sap-1a transcription factor (5), and JNK may influence p53 (6, 7) and NF-kappa B pathways (8, 9). c-Jun, a component of the transcription factor AP-1 complex is the most characterized downstream target of JNK, where regulation is achieved by phosphorylation at Ser-63 or Ser-73 (3). Extracellular signals such as growth factors, transforming oncoproteins, and UV irradiation stimulate phosphorylation of c-Jun at ser-63/73 and activate c-Jun-dependent transcription. The binding of JNK to the N-terminal region of c-Jun permits substrate phosphorylation. The JNK pathway has also been shown to be important in the control of cell survival and death pathways, and interference with the JNK pathway suppresses the induction of apoptosis by a variety of agents (10).

The glutathione S-transferases (GST) are a multigene family of isozymes that catalyze the nucleophilic attack of the sulfur atom of glutathione on electrophilic groups of substrate molecules. Although catalytic efficiencies for many of the substrates are low, their biological relevance as enzymes has frequently been linked to pleiotropic substrate specificity. Among this family of isozymes, GSTP1-1 is generally the most prevalent in mammalian cells. The link between GST overexpression, especially with respect to GSTP1-1, and anticancer drug resistance has been extensively studied (11). Because of the defined role of GST in drug metabolism, elevated expression of GSTP1-1 in solid tumors or in drug-resistant cells has been associated frequently with detoxification reactions even in instances where there is no evidence that the selecting drug is a substrate for GSTP1-1. More recently, however, the link between the redox active components of GSTP1-1 and stress-activated kinases, such as JNK, has been redefined as a non-catalytic, ligand binding activity that mediates both stress and apoptotic responses (1, 10). In a parallel series of studies, either GSTµ or thioredoxin has also been identified as a ligand-binding partner for apoptosis-signaling kinase (ASK1) (12, 13), extending the role that "redox proteins" may have in kinase regulation. To elucidate further the mechanism by which GSTP1-1 mediates JNK signal transduction, we have used biophysical methods in reconstituted protein systems to provide direct evidence for protein-protein interactions and to measure binding affinities. Our results demonstrate that GSTP1-1 has significant affinity for the C terminus of JNK and confirm the ligand-binding regulatory role for this ubiquitously expressed protein.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Protein Purification-- Recombinant JNK1 protein was expressed in Escherichia coli. The polymerase chain reaction product was constructed with a leader His-tag, digested with NdeI and BamHI, purified, and ligated into NdeI-digested, BamHI-digested, and phosphatase-treated pET-15b to create JNK.pET-15b. The JNK1 protein was expressed in E. coli and purified using a standard Ni2+ column for His-tagged proteins. The purified protein was homogeneous as judged by the single polypeptide band of the predicted Mr on silver-stained SDS-polyacrylamide gels (data not shown).

Both the C-terminal and N-terminal truncated proteins expressed in E. coli were found mainly in the insoluble fraction of the bacterial extracts. Thus, inclusion bodies were solubilized in 50 mM CAPS (3-(cyclohexylamino)-1-propanesulfonic acid), pH 11.0, with 0.3% N-lauroylsarcosine supplemented with 1 mM dithiothreitol and slowly diluted to 20 mM Tris-HCl, pH 8.5, before subjection to Ni2+ column chromatography. Renaturation was accomplished by dialyzing for 12 h at 4 °C with a change of buffer with dithiothreitol and continued dialysis for an additional 6 h. To promote refolding, a further period of dialysis in the above buffer (20 mM Tris, pH 8.5) without dithiothreitol for the same length of time was enacted.

The GSTP1-1 construct was made by direct digestion of GSTP1-1 from PCR2.1(+) with HindIII and XhoI followed by cloning into pET21 vector previously treated with HindIII and XhoI. This was expressed in E. coli, and protein was purified using GSH affinity chromatography.

Circular dichroic spectra of the C-terminal and N-terminal JNK1 in 20 mM PO43+ were obtained using an Aviv 62A DS spectrometer at the Fox Chase Cancer Center core facility. The corresponding structural elements were calculated using an algorithm for the estimation of the percentages of protein secondary structure from UV circular dichroism spectra using a Kohonen neural network with a two-dimensional output layer using K2D software (14, 15). The program uses a self-organizing neural network to extract the secondary structure features present in the data from a set of circular dichroism spectra ranging from 200-241 nm. The result provides an estimate of percentage helix, beta -sheet, and random structure for the protein. K2D also estimates the probable error in the estimation based on the training procedure results.

Protein Labeling and Reconstitution-- GSTP1-1 was labeled at a 1:1 molar ratio (probe:protein) with the fluorescence energy transfer donor 7-methoxycoumarin succinyl ester using previously described procedures (16). The JNK1 partner proteins (full-length and partial) were similarly labeled with the non-fluorescence energy transfer acceptor, 4(dimethylamino) phenylazophenyl-4-sulfonyl chloride succinyl ester (Molecular Probes Inc., Eugene, OR). The protein:probe labeling ratios were determined by absorption spectroscopy (17) using the calculated extinction coefficients for the protein and the coefficients provided by the probe manufacturer.

Cells and Protein Preparation-- NIH3T3 mouse fibroblast cells that stably express the pSV40-Hyg plasmid (CLONTECH, Palo Alto, CA) were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and antibiotics (Life Technologies Inc.). Cells were grown at 37 °C with 5% CO2. The pTet-C-JNK was assembled by subcloning the cDNA of the C-terminal 224 amino acids of wild type JNK1 into the tet-regulated promoter of the pUHD-10-3 vector. Cell clones that stably express both constructs were selected in 600 µg/ml geneticin in the presence of hygromycin (100 µg/ml) 24 h after N,N,N-trimethyl 1-2-3-bis (1-oxo-9-octa-decenyl)oxy-(Z,Z)-1-propanaminium methyl sulfate transfection with the pTet-C-JNK-UHD-10-3 construct. Cells expressing C-terminal JNK were maintained in Dulbecco's modified Eagle's medium containing fetal bovine serum (10%), hygromycin (100 µg/ml), and geneticin (400 µg/ml). To maintain suppression of C-terminal JNK expression, tetracycline was added to the medium every 3 days (to a final concentration of 1 µg/ml). Analysis of JNK1 activity was achieved by measurement of phosphorylation of c-Jun as a substrate (1).

Antibodies, Immunoprecipitation, and Immunoblotting-- Antibodies to C-JNK and phospho-c-Jun were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and New England BioLabs (Beverly, MA). Immunoblot analysis was performed using 200 µg of whole cell extract (WCE) separated on SDS-polyacrylamide gel electrophoresis followed by electrotransfer to a polyvinylidene difluoride membrane in 20 mM CHAPS (3-(3-cholamidopropyl) dimethylammonio-1-propane-sulfonate)) buffer, pH 11, for 30 min membrane blocking (5% non-fat milk) and incubating with the respective antibodies. Reactions were visualized using chemiluminescence (ECL) reagents. Immunoprecipitations were carried out following the protocol from the manual provided by Roche Diagnostics Corporation using 1 mg of WCE and 2 µg of the respective antibodies for 16 h at 4 °C. Protein G beads (Roche Molecular Biochemicals) were added (15 µl) for 4 h at 4 °C. Immunoprecipitated material was subjected to immunoblot analysis.

Protein Kinase Assays-- Protein kinase assays were carried out using JNK kinase assay kits from New England BioLabs according the to manufacturer's instructions. The kinase reaction was carried out in the presence of excess unlabeled ATP. c-Jun phosphorylation was selectively measured using a phospho-c-Jun antibody. This antibody specifically measures JNK-induced phosphorylation of c-Jun at Ser-63, an important site for c-Jun-dependent transcriptional activity.

Fluorescence Resonance Energy Transfer Experiments-- Associations between GSTP1-1 and JNK were measured by fluorescence resonance energy transfer (FRET) as described previously (16). Protein concentrations were measured using UV absorption (A280) and colorimetric assays. Extinction coefficients for each protein were assessed as described previously (18). FRET was performed on a PC1 (photon counting) spectrofluorimeter (ISS, Inc., Champagne, IL) using a 3-mm cuvette with a magnetic stirrer. Coumarin-labeled proteins were excited at 350 nm and scanned from 380-480 nm. To determine the binding affinities for protein-protein interactions, the energy transfer data were analyzed using Sigma Plot.

Data Analysis-- All immunoblot and SDS-polyacrylamide gel electrophoresis gels were scanned using a UMAX Powerbook III flatbed with Adobe Photoshop software. Scanned images were quantified by NIH image program. Prism software was used for data analysis.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Purification of JNK Proteins-- Full-length JNK1 was soluble and purified directly by Ni2+ chromatography. Both truncated forms were insoluble in aqueous buffer and were initially solubilized in detergent followed by slow dialysis against renaturing buffers. The renatured proteins were then similarly purified by Ni2+ chromatography. The purity of these proteins was confirmed by single band staining on SDS-polyacrylamide gel electrophoresis (data not shown).

Circular dichroism of these purified proteins was used to monitor the refolding process. Fig. 1 shows the proportional secondary structure of the truncated fragments derived from the circular dichroism spectra. These data were analyzed further using a Kohonen neural network with two-dimensional output layer using K2D software (14, 15). JNK1 shows a >95% identity to JNK3, a protein which has been crystallized (19). The C-terminal of JNK3 is comprised primarily of alpha -helices, whereas the N-terminal is predominantly comprised of beta -sheet. Such structures are in agreement with the data shown in Table I, confirming that accurate folding in solution has occurred.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 1.   Circular dichroic spectra of (A) C-terminal JNK1 and (B) N-terminal JNK1 solubilized in 20 mM phosphate buffer (pH 7.2). Data were collected at room temperature. Spectra were fit to secondary structural elements that are listed under "Experimental Procedures" and analyzed to yield the secondary structures listed in Table I.

                              
View this table:
[in this window]
[in a new window]
 
Table I
K2D software analysis of circular dichroism results

FRET Analysis of GSTP1-1 Association with JNK-- In vitro association kinetics between the purified JNK proteins and GSTP1-1 was analyzed using (FRET) and is shown in Fig. 2. GSTP1-1 was labeled with the succinyl ester of 7-methoxycoumarin. Full-length and truncated JNK1 was labeled with the non-fluorescence energy transfer acceptor, 4-(dimethylamino) phenylazophenyl-4-sulfonyl chloride succinyl ester. Saturation binding experiments were used to measure the specific binding at equilibrium at various concentrations of the fluorescent acceptor protein to determine acceptor affinity. Fig. 2A shows that for the full-length JNK1 a loss in 7-methoxycoumarin fluorescence was observed as the protein interacted with GSTP1-1. A similar result was found for the C-terminal fragment (Fig. 2B), while neither the N-terminal fragment nor buffer conditions produced any change in fluorescence. The calculated Kd for GSTP1-1 association with full-length JNK1 was 188 ± 38 nM and for the C-terminal fragment, 217 ± 72 nM. These data provide quantitative evidence for the direct protein-protein interaction between GSTP1-1 and JNK1.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 2.   Binding GSTP1-1 to full-length or truncated JNK1. The FRET assay was carried out as described under "Experimental Procedures" at room temperature. GSTP1-1 labeled with 7-methoxy coumarin (20 nM) titrated with either N- or C-terminal JNK and full-length JNK labeled with dabsyl (DAB). The reaction buffer contained 20 mM Hepes and 150 mM NaCl. A, the normalized decrease in the fluorescence intensity obtained by dividing the zero-point fluorescence intensity with background subtraction of 2 nM methoxycoumarin labeled GSTP1-1 titrated with full-length JNK1 (), N-terminal-JNK1 (black-triangle), or buffer only (black-square). B, the association of GSTP1-1 with C-terminal JNK1 under the same experimental procedures as Fig. 4A; C-terminal JNK (black-square).

Immunoprecipitation Analysis of GSTP1-1-C-JNK Association-- These results were extended to a cellular system by using a tet-inducible construct of HA-tagged C-JNK. To measure the in vivo association of C-JNK and GSTP1-1, immunoprecipitation of WCE from cells expressing HA-tagged C-JNK was performed. Induction of C-JNK expression following removal of tetracycline resulted in an enhanced level of GSTP1-1 co-immunoprecipitation when an HA-tag antibody was used (Fig. 3).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 3.   Co-immunoprecipitation of GSTP1-1 with C-JNK. HA antibody was added to WCE. Protein G beads were added to the mixture to pull down HA-tagged C-JNK followed by immunoblotting with GSTP1-1 polyclonal antibodies. Endogenous GSTP1-1 expression levels stayed the same throughout the 48 h induction after removal of tetracycline. The histogram quantified (mean ± S.D. of three experiments) that the GST association with C-JNK increased as more C-JNK was expressed.

These data are consistent with the conclusion that C-JNK and GSTP1-1 interact in a cellular milieu. Similarly, the intracellular expression of the C-terminal truncated form of JNK1 leads to an increase in JNK1 kinase activity as a consequence of competing for the GSTP1-1 binding site and liberating catalytically active JNK1 (see Fig. 5).

C-JNK Blocks the Interaction between GSTP1-1 and Full-length JNK and Increases JNK Enzymatic Activity-- For confirmation that the C-terminal portion of JNK1 is critical to the JNK1-GSTP1-1 interaction, a tetracycline-inducible expression system was used to examine whether the increased expression of the C-terminal truncated JNK1 could have a dominant-negative effect upon GSTP1-1 inhibition of JNK1 activity. Fig. 4 shows the time-dependent increase in expression of the C-terminal truncated JNK1 fragment following removal of tetracycline. Induction of the C-terminal fragment was detected by 1 h and persisted for at least 48 h. In these same cells, full-length JNK1 expression was constitutive and unaltered throughout this period (Fig. 4). JNK1 activity was measured by the phosphorylation of the downstream c-Jun substrate (Fig. 5). The time-dependent increase in phosphorylated c-Jun was coincident with the enhanced expression of the truncated C-terminal fragment. If tetracycline was not removed from the media, there was no enhanced production of phosphorylated c-Jun product (Fig. 5). Overall, these results support the conclusion that the C-JNK fragment through competitive binding with GSTP1-1 can act in a dominant-negative fashion and increase the catalytic activity of JNK1.


View larger version (45K):
[in this window]
[in a new window]
 
Fig. 4.   A), induction of protein expression of C-terminal JNK in NIH3T3 cells by removal of tetracycline. HA-tagged C-JNK (residues 200-424) was used to establish NIH3T3 cells that are tet-regulatable. NIH3T3 cells transfected with ptet-C-JNK-UHD-10-3 were harvested at different time points for protein isolation after tetracycline removal. WCE were analyzed on 12% polyacrylamide gels. Immunoblot analysis revealed the expression of a 30-kDa protein detected with polyclonal antibodies to C-JNK1. B, expression of full-length JNK1 under the same conditions. The full-length JNK protein was used to monitor equal loading for each lane. Immunoblots were scanned and quantified by NIH image software. The final results were plotted as histograms and are mean ± S.D. of three experiments.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 5.   JNK kinase activity in the presence of truncated C-terminal JNK expression. Cells were harvested at the indicated time points (hours) after removal of tetracycline. c-Jun fusion protein beads were added to the WCE. Equal amounts of total cell lysate (~200 µg of protein) were electrophoresed on 12% polyacrylamide gels. Immunoblot detection was performed using the ECL system with rabbit monoclonal antibodies to phosphorylated c-Jun (top panel) for the detection of JNK kinase catalytic activity or c-Jun (bottom panel). Absorption was quantified and plotted in arbitrary units in the presence (black-triangle) or absence (black-square) of tetracycline.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Glutathione S-transferases are a multigene family of isozymes that primarily have been linked functionally with phase II metabolism or xenobiotics. In particular, GSTP1-1 is frequently overexpressed in solid tumors and in cells that have acquired resistance to anticancer drugs even when the selected drug is not a GST substrate (11). The precise reason for the high levels of expression in tumor cells has not been explained adequately. Recently, we have carried out a series of studies to show that GSTP1-1 can act as a ligand-binding protein and an endogenous switch for the control of the catalytic activity of JNK1 (1, 10). This has led to other studies implicating that GSTP1-1 is in control of apoptosis (20). Maintenance of cellular kinases that influence cell growth and apoptosis must be finely tuned. In particular, external stimuli such as reactive oxygen species may influence signaling kinase activities, influencing pathways in stress response and cell survival (21). It now seems reasonable to conclude that GSTP1-1 can elicit protection against apoptosis induced by reactive oxygen species by controlling the balance of kinase activity elicited by JNK1 versus other cellular kinases such as extracellular signal regulated kinase, Ikappa B kinase, and p38 (1, 10). Our earlier experiments showing interactions between GSTP1-1 and JNK1 relied primarily on immunoprecipitation technology. In this report, we combine a number of technical approaches to provide evidence for direct protein-protein interaction between GSTP1-1 and JNK1. These data also establish quantitative binding kinetics for these two proteins with Kd values in the nanomolar range. The specificity of the C terminus of JNK1 was confirmed by a number of controls that included the N-terminal and other unlabeled proteins, all of which failed to bind. The affinity of the truncated C-JNK fragment for GSTP1-1 was similar to the full-length protein.

JNK1 shares a high level of amino acid identity with JNK3 (Fig. 6). By extrapolation, we were able to establish that the folding pattern of the C-terminal truncated JNK1 was similar to the structure of JNK3 established by crystallography data (19). Both the in vitro and cellular data confirmed that the truncated C-terminal JNK1 contained amino acid residues that can be implicated in the binding to GSTP1-1. A recent study (22) has used computation of average structures to reveal that residues 194-201 of GSTP1-1 may be involved in the interaction with JNK. This sequence (SSPEHVNR) contains residues that are positively charged or contain polar groups in their side chains. Sequence analysis of the C terminus of JNK1 shows both a loop region and an alpha -helix rich in negatively charged residues, particularly glutamic and aspartic acid (Fig. 6). These residues are either in the flexible loop structure (Asp-377, Asp-381, Glu-382, Glu-384) or the alpha -helix (Glu-388, Glu-389, Glu-392, Glu-397, Asp-400, Glu-402, Glu-403) of the protein and can form a negatively charged binding face capable of interacting with GSTP1-1. This, in turn, is on the surface of JNK1 and therefore in a location conducive to protein-protein interaction with GSTP1-1. Fig. 6 shows the sequence alignments for the C-terminal components of JNK family members (19). The potential interaction site implicated in the molecular dynamic analysis (22) is distal to the GST subunit dimerization domain (involving Cys-47 and Cys-101) (23) suggesting that JNK may interact in vivo with homodimeric GSTP1-1. In addition, because the catalytic kinase domain is localized in the N-terminal of JNK1, our results suggest that the capacity of GSTP1-1 to suppress JNK enzyme activity will be through an allosteric inhibition mechanism.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 6.   Multiple sequence alignment of JNK proteins using the program MAC showing conserved sequence homology among JNK proteins. A cluster of acidic residues (marked in light gray) are possible sites interacting with the basic residues of GSTP1-1 identified by Monaco et al. (22).

This information may be facile in the design of potential small molecule inhibitors of the ligand-binding properties of these two proteins. Targeting this area on JNK1 may impact kinase expression and, by extrapolation, influence apoptosis (10). We have previously shown that a peptidomimetic inhibitor of GSTP1-1 (24) causes a dissociation of the GSTP1-1-JNK1 complex resulting in increased JNK catalytic activity (1). This drug has significant effects on proliferative pathways in bone marrow cells.2 It is plausible that pharmacological manipulation with such agents could achieve control of the coordinated regulation of stress kinases with a significant impact in the therapy of cancer.

    ACKNOWLEDGEMENTS

We thank Zhiming Yin for providing the partial JNK constructs, Ma Jinguo for the NIH3T3 tet-off cell system, and Dr. Suzanne Scarlata for use of ISIS instrumentation.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grants CA06927 and RR05539, National Institutes of Health Grant CA85660 (to KDT), National Institutes of Health Grant CA77389 (to ZR), and by an appropriation from the Commonwealth of Pennsylvania.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of Pharmacology, Fox Chase Cancer Center, 7701 Burholme Ave., Philadelphia, PA 19111. Tel.: 215-728-3147; Fax: 215-728-4333; E-mail: kd_tew@fccc.edu.

Published, JBC Papers in Press, March 9, 2001, DOI 10.1074/jbc.M101355200

2 Ruscoe, J. E., Rosario, L. A., Wang, T., Gate, L., Arifoglu, P., Wolf, C. R., Henderson, C. J., Ronai, Z., and Tew, K. D. (2001) J. Pharmocol. Exp. Ther., in press.

    ABBREVIATIONS

The abbreviations used are: JNK, c-jun N-terminal kinase; MAPK, mitogen-activated protein kinase; GST, glutathione S-transferases; ASK, apoptosis-signaling kinase; WCE, whole cell extract; FRET, fluorescence resonance energy transfer; HA, hemagglutinin; ECL, enhanced chemiluminescence.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Adler, V., Yin, Z., Fuchs, S. Y., Benezra, M., Rosario, L., Tew, K. D., Pincus, M. R., Sardana, M., Henderson, C. J., Wolf, C. R., Davis, R. J., and Ronai, Z. (1999) EMBO J. 18, 1321-1334[Abstract/Free Full Text]
2. Ip, Y. T., and Davis, R. J. (1998) Curr. Opin. Cell Biol. 10, 205-219[CrossRef][Medline] [Order article via Infotrieve]
3. Gupta, S., Campbell, D., Derijard, B., and Davis, R. J. (1995) Science 267, 389-393[Medline] [Order article via Infotrieve]
4. Whitmarsh, A. J., Shore, P., Sharrocks, A. D., and Davis, R. J. (1995) Science 269, 403-407[Medline] [Order article via Infotrieve]
5. Janknecht, R., and Hunter, T. (1997) J. Biol. Chem. 272, 4219-4224[Abstract/Free Full Text]
6. Fuchs, S. Y., Adler, V., Pincus, M. R., and Ronai, Z. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 10541-10546[Abstract/Free Full Text]
7. Buschmann, T., Yin, Z., Bhoumik, A., and Ronai, Z. (2000) J. Biol. Chem. 275, 16590-16596[Abstract/Free Full Text]
8. Meyer, C. F., Wang, X., Chang, C., Templeton, D., and Tan, T. H. (1996) J. Biol. Chem. 271, 8971-8976[Abstract/Free Full Text]
9. Lee, F. S., Hagler, J., Chen, Z. J., and Maniatis, T. (1997) Cell 88, 213-222[Medline] [Order article via Infotrieve]
10. Yin, Z., Ivanov, V., Habelhah, H., Tew, K. D., and Ronai, Z. (2000) Cancer Res. 60, 4053-4057[Abstract/Free Full Text]
11. Tew, K. D. (1994) Cancer Res. 54, 4313-4320[Abstract]
12. Saitoh, M., Nishitoh, H., Fuji, M., Takeda, K., Tobiume, K., Sawada, Y., Kawabata, M., Miyazono, K., and Ichijo, H. (1998) EMBO J. 17, 2596-2606[Abstract/Free Full Text]
13. Cho, S.-G., Lee, Y. H., Park, H.-S., Ryoo, K., Kang, K. W., Park, J., Eom, S.-J., Kim, M. J., Chang, T.-W., Choi, S.-Y., Shim, J., Kim, Y., Dong, M.-S., Lee, M.-J., Kim, S. G., Ichijo, H., and Choi, E.-J. (2001) J. Biol. Chem., in press
14. Andrade, M. A., Chacon, P., Merelo, J. J., and Morán, F. (1993) Protein Eng. 6, 383-390[Abstract]
15. Merelo, J. J., Andrade, M. A., Prieto, A., and Morán, F. (1994) Neurocomputing 6, 443-454[CrossRef]
16. Wang, T., Dowal, L., El-Maghrabi, M. R., Rebecchi, M., and Scarlata, S. (2000) J. Biol. Chem. 275, 7466-7469[Abstract/Free Full Text]
17. Gill, S. C., and von Hippel, P. H. (1989) Anal. Biochem. 182, 319-326[Medline] [Order article via Infotrieve]
18. Wang, T., Pentyala, S., Elliott, J. T., Dowal, L., Gupta, E., Rebecchi, M. J., and Scarlata, S. (1999) Proc. Natl. Acad. Sci. U. S. A. 6, 7843-7846[CrossRef]
19. Xie, X., Gu, Y., Fox, T., Coll, J. T., Fleming, M. A., Markland, W., Caron, P. R., Wilson, K. P., and Su, M. S. (1998) Structure 6, 983-991[Medline] [Order article via Infotrieve]
20. Bernardini, S., Bernassola, F., Cortese, C., Ballerini, S., Melino, G., Motti, C., Bellincampi, L., Iori, R., and Federici, G. (2000) J. Cell. Biochem. 77, 645-653[CrossRef][Medline] [Order article via Infotrieve]
21. Davis, W., Jr., Ronai, Z., and Tew, K. D. (2001) J. Pharmacol. Exp. Ther. 296, 1-6[Abstract/Free Full Text]
22. Monaco, R., Friedman, F. K., Hyde, M. J., Chen, J. M., Manolatus, S., Adler, V., Ronai, Z., Koslosky, W., and Pincus, M. R. (1999) J. Protein Chem. 18, 859-866[Medline] [Order article via Infotrieve]
23. Garcia-Saez, I., Parraga, A., Phillips, M. F., Mantle, T. J., and Coll, M. (1994) J. Mol. Biol. 237, 298-314[CrossRef][Medline] [Order article via Infotrieve]
24. Morgan, A. S., Ciaccio, P. J., Tew, K. D., and Kauvar, L. M. (1996) Cancer Chemother. Pharmacol. 37, 363-370[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.